Claims:

1. A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, the composition is free of histidine and the GLP-1 agonist is in an amount of 0.01 mg/ml to 1.5 mg/ml.

2. The liquid composition as claimed in claim 1, wherein the composition comprises a pharmaceutically acceptable preservative, more particularly m-cresol.

3. The liquid composition as claimed in claim 1 or 2, wherein the composition comprises glycerol.

4. The liquid composition as claimed in any one of the preceding claims, wherein the composition has a pH in the range from 3.5 to 5.

5. The liquid composition as claimed in any one of the preceding claims, wherein the composition comprises methionine in an amount ranging from 0.5 mg/mL to 20 mg/mL, preferably in an amount ranging from 1 mg/mL to 5 mg/mL.

6. The liquid composition as claimed in any one of the preceding claims, wherein the GLP-1 agonist is selected from the group consisting of GLP-1, exendin-3 , exendin-4 , wherein the GLP-1 agonist is

preferably selected from the group consisting of desPro^{36}exendin-4(1-39)-Lys$_6$-NH$_2$ and exendin-4.

7. The liquid composition as claimed in any one of the preceding claims, wherein the composition has the following constituents:
   (a) desPro^{36}exendin-4(1-39)-Lys$_6$-NH$_2$,
   (b) sodium acetate,
   (c) m-cresol,
   (d) L-methionine,
   (e) 85% glycerol,
   (f) approximately 0.1 N hydrochloric acid, if adjustment to a pH of approximately 4.5 is required,
   (g) approximately 0.1 N NaOH solution, if adjustment to a pH of approximately 4.5 is required, and
   (h) water.

8. The composition as claimed in any one of the preceding claims, wherein the composition is an injectable composition.

9. The composition as claimed in any one of the preceding claims for treating diabetes mellitus.

10. The use of a composition as claimed in any one of claims 1 to 9 in the manufacture of a pharmaceutical for treating diabetes mellitus, more particularly type II diabetes.

11. A method for manufacturing a composition as claimed in any one of claims 1 to 9, comprising formulating a GLP-1 agonist or/and a pharmacologically tolerable salt thereof with methionine and, optionally, at least one pharmaceutically acceptable excipient.

12. A composition as claimed in any one of claims 1 to 9 for use as a pharmaceutical.
13. Use of the composition as claimed in any one of preceding claims 1 to 8 in the manufacture of a pharmaceutical for treating diabetes mellitus and/ or obesity, wherein said pharmaceutical is to be administered with metformin, a sulfonylurea, a glitazone, and/or a long-acting insulin/insulin derivate, and/or a combination thereof, and/or a pharmacologically tolerable salt to a patient in need thereof.

14. The use as claimed in claim 10 or 13, comprising an add-on therapy in patients where sufficient blood sugar control could not be achieved with metformin, a sulfonylurea, a glitazone, and/or a long-acting insulin/insulin derivate.

15. The use of the composition as claimed in claim 10, or 13 or 14, wherein the treated patients have an HbA1c value in the range from 7% to 10%.

16. The use of the composition as claimed in claim 13 wherein diabetes mellitus is type II diabetes.

17. The use of the composition as claimed in any one of claims 10, and 13 to 16 and wherein said composition is to be administered in patients with type II diabetes as a supplement to a diet in order to improve blood sugar control.

18. The use of the composition as claimed in any one of claims 10 and 13 to 17, wherein said composition is to be administered in patients once a day.

Claims:

1. A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, wherein the GLP-1 agonist is desPro^{36}exendin-4(1-39)-Lys_6-NH^2, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, the composition is free of histidine and the GLP-1 agonist is in an amount of 0.01 mg/ml to 1.5 mg/ml.

2. The liquid composition as claimed in claim 1, wherein the composition comprises a pharmaceutically acceptable preservative, more particularly m-cresol.

3. The liquid composition as claimed in claim 1 or 2, wherein the composition comprises glycerol.

4. The liquid composition as claimed in any one of the preceding claims, wherein the composition has a pH in the range from 3.5 to 5.

5. The liquid composition as claimed in any one of the preceding claims, wherein the composition comprises methionine in an amount ranging from 0.5 mg/mL to 20 mg/mL, preferably in an amount ranging from 1 mg/mL to 5 mg/mL.

6. The liquid composition as claimed in any one of the preceding claims, wherein the composition has the following constituents:
   (a) desPro^{36}exendin-4(1-39)-Lys_6-NH_2,
   (b) sodium acetate,
   (c) m-cresol,
   (d) L-methionine,
   (e) 85% glycerol,
   (f) approximately 0.1 N hydrochloric acid, if adjustment to a pH of approximately 4.5 is required,
   (g) approximately 0.1 N NaOH solution, if adjustment to a pH of approximately 4.5 is required, and
   (h) water.

7. The composition as claimed in any one of the preceding claims, wherein the composition is an injectable composition.

8. The composition as claimed in any one of the preceding claims for treating diabetes mellitus.

9. The use of a composition as claimed in any one of claims 1 to 8 in the manufacture of a pharmaceutical for treating diabetes mellitus, more particularly type II diabetes.

10. A method for manufacturing a composition as claimed in any one of claims 1 to 8, comprising formulating a GLP-1 agonist or/and a pharmacologically tolerable salt thereof with methionine and, optionally, at least one pharmaceutically acceptable excipient.

11. A composition as claimed in any one of claims 1 to 8 for use as a pharmaceutical.

12. Use of the composition as claimed in any one of preceding claims 1 to 7 in the manufacture of a pharmaceutical for treating diabetes mellitus and/ or obesity, wherein said pharmaceutical is to be administered with metformin, a sulfonylurea, a glitazone, and/or a long-acting insulin/insulin derivate, and/or a combination thereof, and/or a pharmacologically tolerable salt to a patient in need thereof.

13. The use as claimed in claim 9 or 12, comprising an add-on therapy in patients where sufficient blood sugar control could not be achieved with metformin, a sulfonylurea, a glitazone, and/or a long-acting insulin/insulin derivate.

14. The use of the composition as claimed in claim 9, or 12 or 13, wherein the treated patients have an HbA1c value in the range from 7% to 10%.

15. The use of the composition as claimed in claim 12 wherein diabetes mellitus is type II diabetes.

16. The use of the composition as claimed in any one of claims 9, and 12 to 15 and wherein said composition is to be administered in patients with type II diabetes as a supplement to a diet in order to improve blood sugar control.

17. The use of the composition as claimed in any one of claims 9 and 12 to 16, wherein said composition is to be administered in patients once a day.